We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

FDA Approves Use of Velcade for Retreatment of Myeloma
The US FDA has approved the use of Velcade for retreatment of myeloma patients who have previously responded to Velcade and have relapsed at least six months after their prior treatment. The expanded approval was granted based on data from a phase II clinical trial. This approval includes IV and subcutaneous forms of Velcade.

Cancer Cases Among 9/11 Early Responders Continue to Grow
More cancer cases are being reported among 9/11 rescuers and responders, with more than 2,500 people with cancer now included in World Trade Center health programs. Myeloma is covered under the 9/11 Victim Compensation Fund, and studies have shown that 9/11 workers have gotten myeloma at a higher rate than expected in the normal population. Research has also shown a relationship between myeloma and exposure to carcinogens located at the World Trade Center site. IMF Chairman Dr. Brian Durie has written extensively on myeloma and toxins, and in his blog this week, he examines this troubling growth in cases.

#AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


Summer 2014 Edition of Myeloma Today

Articles include:

  • Key Questions 2014: Highlights from the 5th Annual IMWG Summit
  • Highlights from the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Living Well With Myeloma:  Expert Advice on Pain Management


Raise Your Voice: Advocacy 202 - Replay
Did you miss the Raise Your Voice: Advocacy 202 webinar last month? Have no fear, you can watch, listen and learn right from your computer today! The webinar focused on how to meet with your Member of Congress and ask for support of HR 1801, The Cancer Drug Coverage Parity Act and S 1879, The Cancer Treatment Parity Act. With enough voices, we can improve the quality of life for myeloma patients by building support for equal access to treatment. Watch the webinar to learn how you can make a difference.

The International Myeloma Foundation (IMF) Celebrates Maine’s Oral Anticacer Treatment Access Law Taking Effect

The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure –  today celebrates Maine’s Oral Anticancer Treatment Access Law taking effect. The law directs health benefit plans that provide coverage for cancer chemotherapy treatment to extend coverage for orally administered anticancer medications at a cost equal to the cost of intravenously administered or injected anticancer medications. 


Frontline Therapy and MRD: Exciting New Data from France
Minimal residual disease (MRD) measurement through flow cytometry was shown to be a meaningful predictor in a frontline myeloma study published this month in the Journal of Clinical Oncology. In his blog, IMF Chairman Dr. Brian Durie explains that patients who achieved MRD-negative status remain in remission after a median follow-up of three years. This study “points the way to incorporation of MRD testing by flow cytometry into tailored approaches to achieve the very best results with therapy throughout the course of disease,” said Dr. Durie.

IMF Supports Support Group Leaders During 15th Annual Summit
Nearly 100 myeloma support group leaders gathered in Dallas, Texas over the weekend for the IMF's 15th Annual Support Group Leaders Summit. "During the year, these leaders give their all to their myeloma support groups," said Robin Tuohy, IMF Senior Director of Support Groups. "At the Summit, we give THEM as much as we can so they can share with their members the latest news about myeloma treatment, clinical trials, best practices for running a support group, and - perhaps most important of all - a chance to create lifelong bonds with fellow leaders across the nation." Leaders were instructed in the practice of tai chi (right) as a relaxation tool to pass along to their members.

Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays

This booklet is devoted to two tests used in the diagnosis and monitoring of myeloma, the serum free light chain assay (Freelite®) and the serum heavy/light chain assay (Hevylite®). Since Freelite and Hevylite are independent biomark­ers of disease activity, it is important to monitor patients with both tests. 


IMF Unveils New Logo
Ushering in a new phase for the IMF and myeloma patients, the new logo reflects forward movement and hopefulness. This mirrors the significant progress being made in myeloma treatment, including the exceptional progress being made under the IMF’s signature Black Swan Research Initiative® to find a pathway to a cure for myeloma.

previous     next      view all